Study for the pathogenesis of eosinophilic polyangiitis granulomatosis (EGPA)

Study for the pathogenesis of eosinophilic polyangiitis granulomatosis (EGPA) - Study for the pathogenesis of eosinophilic polyangiitis granulomatosis (EGPA)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040163

Enrollment

100

Registered

2020-04-20

Start date

2020-04-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eosinophilic granulomatosis with polyangiitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who were diagnosed as follows in this hospital after April 2000 A. Cases diagnosed with EGPA B. Cases of bronchial asthma that do not meet A

Exclusion criteria

Exclusion criteria: Individuals who are judged to be ineligible by the study representative or the treating physician

Design outcomes

Primary

Measure	Time frame
Differences in microRNA Expression between EGPA and Non EGPA Cases	—

Secondary

Measure	Time frame
1. Quantitative differences in cytokines/chemokines between EGPA and non EGPA cases. 2. Differences in microRNA Expression in EGPA Cases Before (= Active stage) and After several treatment (= Stable stage) 3. Quantitative Differences in Cytokines and Chemokines in EGPA Cases Before and After several treatment	—

Countries

Japan

Contacts

Public ContactYosuke Kamide

Sagamihara National Hospital Clinical Research Center for Allergy and Rheumatology

m08702012@gunma-u.ac.jp042-742-8311

Outcome results